| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Fenoprofen targets cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2, which are involved in the production of prostaglandins that mediate inflammation, pain, and fever. By inhibiting COX enzymes, fenoprofen reduces prostaglandin synthesis. It is pharmacologically similar to aspirin but causes less gastrointestinal bleeding.
|
|---|---|
| ln Vitro |
In vitro, fenoprofen inhibits COX-1 and COX-2 activity, reducing prostaglandin production in cell-based and cell-free assays. Its anti-inflammatory and analgesic activities are assessed by measuring the inhibition of prostaglandin E2 (PGE2) production in stimulated cells. The compound's activity is compared to that of other NSAIDs.
|
| ln Vivo |
In vivo, fenoprofen is used clinically for the treatment of mild to moderate pain and for the relief of pain and inflammation caused by conditions such as arthritis. It is administered orally and is pharmacologically similar to aspirin but causes less gastrointestinal bleeding. The compound is available as the calcium salt dihydrate formulation.
|
| Enzyme Assay |
In vitro enzyme assays for fenoprofen measure its inhibition of COX-1 and COX-2 activity. The enzyme is incubated with arachidonic acid substrate and varying concentrations of the compound. Prostaglandin production is quantified by ELISA or other immunoassay methods. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for fenoprofen use immune cells such as macrophages or whole blood. Cells are stimulated with inflammatory stimuli (e.g., LPS), and prostaglandin production is measured by ELISA. The compound's effects on cell viability and cytokine production are assessed in parallel. Anti-inflammatory activity is confirmed by inhibition of pro-inflammatory mediator production.
|
| Animal Protocol |
In vivo animal models for fenoprofen include models of inflammation and pain such as the carrageenan-induced paw edema model or the acetic acid-induced writhing test. The compound is administered orally, and its effects on inflammation, pain, and fever are evaluated. Gastrointestinal safety is assessed by examining gastric mucosa for lesions.
|
| ADME/Pharmacokinetics |
Fenoprofen Calcium Dihydrate has a molecular formula of C30H26CaO6·2H2O and a molecular weight of 558.64 g/mol. It is also known as 2-(3-Phenoxyphenyl)propionic Acid Calcium Salt Dihydrate. The compound has a purity of >98.0% and is soluble in DMSO at ≥11.45 mg/mL. It is stored at room temperature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of fenoprofen includes gastrointestinal effects such as nausea, vomiting, and gastric bleeding. The compound is pharmacologically similar to aspirin but causes less gastrointestinal bleeding. It is contraindicated in patients with known hypersensitivity to NSAIDs, active gastrointestinal bleeding, or severe renal impairment.
|
| References | |
| Additional Infomation |
Fenoprofen calcium is the dihydrate form of Fenoprofen calcium salt. It is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and to relieve pain and inflammation caused by conditions such as arthritis. Its pharmacological effects are similar to aspirin, but with less gastrointestinal bleeding. It has multiple pharmacological actions, including NSAID, cyclooxygenase-2 inhibitor, cyclooxygenase-1 inhibitor, antipyretic, and non-narcotic analgesic. It contains anhydrous Fenoprofen calcium. Fenoprofen is a propionic acid derivative used as a NSAID. See also: Fenoprofen calcium (note moved to).
Fenoprofen Calcium Dihydrate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and to relieve pain and inflammation caused by conditions such as arthritis. It is pharmacologically similar to aspirin but causes less gastrointestinal bleeding. The compound is the dihydrate form of fenoprofen calcium salt and is also known as 2-(3-Phenoxyphenyl)propionic Acid Calcium Salt Dihydrate. |
| Molecular Formula |
C30H30CAO8
|
|---|---|
| Molecular Weight |
558.6324
|
| Exact Mass |
522.135
|
| CAS # |
71720-56-4
|
| Related CAS # |
Fenoprofen;29679-58-1;Fenoprofen Calcium;34597-40-5
|
| PubChem CID |
64747
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.664
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
39
|
| Complexity |
265
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VHUXSAWXWSTUOD-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/2C15H14O3.Ca/c2*1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13;/h2*2-11H,1H3,(H,16,17);/q;;+2/p-2
|
| Chemical Name |
calcium;2-(3-phenoxyphenyl)propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~358.01 mM)
H2O : ~1 mg/mL (~3.58 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7901 mL | 8.9505 mL | 17.9009 mL | |
| 5 mM | 0.3580 mL | 1.7901 mL | 3.5802 mL | |
| 10 mM | 0.1790 mL | 0.8950 mL | 1.7901 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
